CCCC Latest Press Releases

-- November 5, 2026 --

C4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights Globe Newswire 7:00 AM

-- November 3, 2026 --

C4 Therapeutics to Participate in Upcoming November Investor Conferences Globe Newswire 7:00 AM

-- November 2, 2026 --

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- October 29, 2026 --

C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders Globe Newswire 7:00 AM

-- October 20, 2026 --

Insmed Appoints Two New Directors to Its Board PRNewswire 7:00 AM

-- September 25, 2026 --

C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting Globe Newswire 7:00 AM

-- September 3, 2026 --

C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting Globe Newswire 7:00 AM

-- August 11, 2026 --

C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Globe Newswire 7:00 AM

-- August 10, 2026 --

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- June 11, 2026 --

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes